Annexin Pharmaceuticals (ANNX.ST) Stock Analysis & AI Equity Report
Annexin Pharmaceuticals (ANNX.ST) overview
Annexin Pharmaceuticals (ANNX.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Annexin Pharmaceuticals reported revenue of SEK 0m and operating profit of SEK -50.5m; the year-end share price was 42.28 SEK and market capitalisation was SEK 19,118m. Annexin Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Annexin Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-08-30. Data will be refreshed during report generation.
About Annexin Pharmaceuticals
Annexin Pharmaceuticals AB (publ) is a clinical-stage biotechnology company focused on developing ANXV, a recombinant form of human Annexin A5. The company is advancing the program for diseases associated with vascular damage and inflammation, with current clinical work in ophthalmology and oncology. Its value drivers include product development, patent protection, and potential future licensing or commercialization.
Generate the Annexin Pharmaceuticals report
Annexin Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Annexin Pharmaceuticals and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.